Juno Therapeutics Inc. (JUNO) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Juno Therapeutics Inc. (JUNO)

An SI Board Since May 2015

Posts	SubjectMarks	Bans	Symbol
84	19	0	JUNO

Emcee: scaram(o)uche	Type: Moderated

Introduction Market Data Compact

Not going to be boring, cell-based cancer immunotherapies.

There have been JUNO-related posts accumulating in other threads. A search will find them. Figured it was time for a devoted thread. Today's story? The Editas deal is supposed to reveal JUNO weakness relative to Cellectis (CLLS), that "allogeneic" has a competitive advantage.

That's today's story. A giant land-grab, deals between innovators flying amok, with a focus on IP that will surface in about three years. It's like 1995, all over again. Heavenly.

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
84	Syncona Ltd, a leading healthcare company focused on founding, building and fund	nigel bates	-	1/23/2020
83	"Another competitor I was unaware of is mentioned: Autolus, which, unlike	nigel bates	-	1/15/2020
82	Class action attorneys are out looking for shareholders who don't feel they	scaram(o)uche	2	1/22/2018
81	$87/share Good. CELG shareholders may not be happy.	scaram(o)uche	-	1/22/2018
80	Dana Mattioli?Verified account @DanaMattioli14m14 minutes ago Back-to-back deal	scaram(o)uche	-	1/16/2018
79	A preview of tomorrow's data, today..... pbs.twimg.com	scaram(o)uche	-	12/10/2017
78	Today's drop attributed to unconfirmed rumors of Celgene being uninterested	tuck	-	11/28/2017
77	ASH abstracts out, and the JCAR017 study called TRANSCEND has produced results J	tuck	-	11/1/2017
76	But you may recall talk of offering it with a money back guarantee (oversimplifi	tuck	-	10/20/2017
75	RSI(14) stands at 54.87, bullish crossover in Stochastics. [graphic]	hollyhunter	-	10/19/2017
74	>> list price of $373k << Very good. Step in right direction. Tha	scaram(o)uche	-	10/18/2017
73	Kite's CAR-T therapy approved about six weeks before PDUFA date with a REMS	tuck	-	10/18/2017
72	Any thoughts on price target for Juno? Does anyone else see Juno being acquired?	bio kid	-	10/2/2017
71	link should be secure, juno vs. kite, thanks to @sesiegler..... drive.google.co	scaram(o)uche	-	9/6/2017
70	Gilead - Kite deal stokes buying in Juno Therapeutics, up 8% premarket CAR-T dev	Julius Wong	-	8/28/2017
69	how to deal with patient crises and deaths in these fragile patient populations	tuck	-	6/13/2017
68	Since my March post, I have traded Juno put sales regularly and done well. Howe	tuck	-	6/13/2017
67	PDUFA data in ALL for NVS' CAR-T therapy is in August. Juno has a small pie	tuck	1	3/30/2017
66	Leucid Bio Ltd. is an early stage competitor going after solid tumors with CAR-T	tuck	-	3/8/2017
65	Thanks for your thoughts. >>I also note that RBC thinks the JUNO pre-cond	tuck	-	3/4/2017
64	Nice comments, tuck. I really never got into it here, but I will comment briefl	Biotech Jim	-	3/4/2017
63	I picked up my third tranche today, wanted to maintain my basis under 22. I k	Biotech Jim	-	3/3/2017
62	We got another chance here. I doubled my sold put position. Cheers, Tuck	tuck	-	3/3/2017
61	Parking the Juno and Kite pipelines here so followers can compare. Kite Pipe J	tuck	2	3/2/2017
60	Done buying JUNO shares for now, that was a huge no-brainer. Biotechs blow ou	Biotech Jim	1	3/2/2017

Go to reply# or date (mm/dd/yy):